Abstract
AbstractNanogels offer hope for precise drug delivery, while addressing drug delivery hurdles is vital for effective prostate cancer (PCa) management. We developed an injectable elastin nanogels (ENG) for efficient drug delivery system to overcome castration-resistant prostate cancer (CRPC) by delivering Decursin, a small molecule inhibitor that blocks Wnt/βcatenin pathways for PCa. The ENG exhibited favourable characteristics such as biocompatibility, flexibility, and low toxicity. In this study, size, shape, surface charge, chemical composition, thermal stability, and other properties of ENG were used to confirm the successful synthesis and incorporation of Decursin (DEC) into elastin nanogels (ENG) for prostate cancer therapy. In vitro studies demonstrated sustained release of DEC from the ENG over 120 h, with a pH-dependent release pattern. DU145 cell line induces moderate cytotoxicity of DEC-ENG indicates that nanomedicine has an impact on cell viability and helps strike a balance between therapeutics efficacy and safety while the EPR effect enables targeted drug delivery to prostate tumor sites compared to free DEC. Morphological analysis further supported the effectiveness of DEC-ENG in inducing cell death. Overall, these findings highlight the promising role of ENG-encapsulated decursin as a targeted drug delivery system for CRPC.
Funder
Department of Science and Technology (DST), SERB
National Research Foundation of Korea by the Ministry of Education, Science, and Technology
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Litwin, M. S. & Tan, H.-J. The diagnosis and treatment of prostate cancer: A review. Jama 317, 2532–2542 (2017).
2. Fontana, F., Raimondi, M., Marzagalli, M., Di Domizio, A. & Limonta, P. Natural compounds in prostate cancer prevention and treatment: mechanisms of action and molecular targets. Cells 9, 460 (2020).
3. Singla, R. K. et al. Natural products for the management of castration-resistant prostate cancer: Special focus on nanoparticles based studies. Front. Cell Dev. Biol. 9, 745177 (2021).
4. Sekhoacha, M. et al. Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules 27, 5730 (2022).
5. Yousefnezhad, M., Davaran, S., Babazadeh, M., Akbarzadeh, A. & Pazoki-Toroudi, H. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy. BioImpacts 13, 241–253 (2023).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献